

<!--
// Original:  Patrick Lewis
// mod: W. Jansen

if (document.layers) {navigator.family = "nn4"}
if (document.all) {navigator.family = "ie4"}
if (window.navigator.userAgent.toLowerCase().match("gecko")) {navigator.family = "gecko"}



descarray = new Array(

/*
:::::::: Texte f&uuml;r die Info-Box ab hier
:::::::: ab hier k&ouml;nnen sie Änderungen vornehmen
:::::::: f&uuml;r jeden PopUp-Text je eine Zeile in Reihenfolge der Links mit Komma am Ende
:::::::: außer beim Letzten (kein Komma)
:::::::: innerhalb der Zeilen keinen Zeilenumbruch
:::::::: WICHTIG !!! innerhalb der Zeilen keine doppelstrichigen Anf&uuml;hrungszeichen
*/

//Ab hier Speakers Astra-Zeneca Vormittag

//Array 0 = Schernthaner, Guntram
"<span style='background-color:FFFFFF;color:#666666;text-align:left; width:450px;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Guntram Schernthaner</strong> <br> <i>Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria</i><br><br></td></tr><tr><td><img src='images/speakers/schernthaner.jpg'></td><td>Guntram Schernthaner is Professor of Medicine at the University of Vienna and Head of the Department of Medicine I at Rudolfstiftung Hospital, Vienna. His many research interests include the immunopathogenesis and immunotherapy of type-I diabetes, insulin resistance, diabetic nephropathy, diabetic retinopathy and gestational diabetes. Professor Schernthaner has held numerous prestigious positions including Vice President of the European Association of Clinical Investigation, President of the European Association for the Study of Diabetes (EASD) 1996 Congress in Vienna and Council Member of the EASD. Professor Schernthaner received the 1982 Bertram Award of the German Diabetes Association and the 1997 Albert Renold Medal of the EASD.</td></tr></table>",
//Array 1 = Gerich, John
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>John E Gerich</strong><br><i>Clinical Research Center at the University of Rochester School of Medicine <br>601 Elmwood Ave., Box MED/CRC, Rochester, NY 14642 </i><br><br></td></tr><tr><td><img src='images/speakers/Gerich-John.jpg'></td><td>John Gerich is Professor of Medicine at the University of Rochester School of Medicine, Rochester, USA, Program Director of the Institution's Clinical Research Center and Head of its Diabetes Research Laboratory. He is an expert in the physiology of diabetes and glucose metabolism, and has made fundamental contributions in the understanding of glucose disposal and insulin resistance. He has been able to bridge his scientific research into direct applications to new drugs for the treatment of type II diabetes. Professor Gerich has served on numerous NIH Study Sections and the National Advisory Boards of the American Diabetes Associations and the Juvenile Diabetes Association. His clinical research work has earned the highest awards from the American Diabetes Association and the Juvenile Diabetes Association. He also received the 2007 Novartis Prize in Diabetes for Long-Standing Achievement. </td></tr></table>",
// Array 2 = Whaley, Jean
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Jean M Whaley</strong><br><i>Bristol-Myers Squibb Company, Princeton, NJ, USA</i><br><br></td></tr><tr><td><img src='images/speakers/Jean-Whaley.jpg' alt='Jean Whaley'></td><td>Jean Whaley is currently Group Director of Diabetes Drug Discovery at Bristol-Myers Squibb (BMS) Research & Development in Princeton, New Jersey, USA.  She received her doctoral degree from the Harvard University School of Public Health, in the Department of Cancer Biology. Following a postdoctoral fellowship in the Department of Neurology and Neurosurgery at the Massachusetts General Hospital in Boston, Dr Whaley joined BMS.  Dr Whaley first worked in the 'Oncology Discovery' group at BMS, before joining the Metabolic Diseases group where she helped to identify multiple drug candidates for type 2 diabetes, including dapagliflozin. Since 2004 she has managed a team of biologists engaged in drug discovery for type 2 diabetes at BMS.</td></tr></table>",
//Array 3 =  Wilding, John
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>John Wilding (CoChair)</strong><br><i>Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK</i><br><br></td></tr><tr><td><img src='images/speakers/JWilding.jpg' alt='John Wilding'></td><td>John  is Professor of Medicine at University Hospital Aintree, Liverpool, UK. He trained in Southampton and at the Hammersmith Hospital, London, UK, where he undertook laboratory-based research into the neurobiology of obesity. He has published over 140 original papers, book chapters and review articles related to his research interests in diabetes and obesity. At University Hospital Aintree Professor  has established a clinical research unit and a specialist multidisciplinary clinic for the management of severely obese patients. His research interests include the role of various hypothalamic neuropeptides in weight control and appetite, and the clinical study of new diabetes treatments and anti-obesity compounds.</td></tr></table>",
//Array 4 = Thomson, Scott
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Scott C Thomson (CoChair)</strong><br><i>School of Medicine, University of California San Diego, San Diego, CA, USA</i><br><br></td></tr><tr><td><img src='images/speakers/thomson.jpg' alt='Scott Thomson'></td><td>Scott Thomson is Professor of Medicine in Residence at the University of California San Diego (UCSD), and Chief of Nephrology, VA San Diego Healthcare System. He trained in medicine at UCSD, before obtaining board certification in nephrology and internal medicine. His research interests focus on the autoregulation of renal function, in particular the elucidation of the basic physiological mechanisms of tubuloglomerular feedback and the examination of the role of altered tubular function as a cause of glomerular hyperfiltration in experimental diabetes. Professor Thomson's nephrology practice includes intensive care nephrology (acute dialysis and continuous renal replacement therapy in the critically ill), transplant nephrology, general nephrology, hypertension, clinical fluid-electrolyte and acid-base physiology and apheresis. He is active in numerous societies including the American Society of Nephrology, the International Society of Nephrology, and the American Heart Association Council for High Blood Pressure Research.</td></tr></table>",
// Ab hier Speakers Astra-Zeneca Nachmittag
//Array 5 = Barnett, Anthony
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Anthony Barnett</strong><br><i>Clinical Director - Diabetes and Endocrinology, Heart of England NHS Foundation Trust</i><br><br></td></tr><tr><td><img src='images/speakers/barnett.jpg' alt='Anthony Barnett'></td><td>Anthony Barnett is Professor of Medicine, Consultant Physician and Clinical Director of Diabetes and Endocrinology at Heart of England NHS Foundation Trust which has one the largest Diabetes and Weight Management Units in the United Kingdom. He gained his medical degree from King's College, University of London. He subsequently trained at a number of hospitals and universities. For 2 years, he held the position of Medical Research Council Senior Fellow in Diabetes at King's College Hospital, London. He subsequently moved to Birmingham and is currently Professor of Medicine at the University of Birmingham. <br>Professor Barnett's research interests include the genetics of diabetes, the causes of complications of diabetes, the development of new therapies to treat diabetes and its long-term vascular complications and Health Service Related Research (including 'difficult to reach' groups). In addition to publishing over 400 original papers, he has written many books, review articles and editorials on diabetes, and has contributed chapters to major textbooks on the subject. He also regularly acts as adviser to NICE, the EMEA and the National Prescribing Centre on diabetes related therapies.</td></tr></table>",
//Array 6 = Bailey, Clifford
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Clifford J. Bailey, PhD, FRCP(Edin), FRCPath</strong><br><i>Life and Health Sciences, Aston University, Birmingham, UK</i><br><br></td></tr><tr><td><img src='images/speakers/bailey.jpg' alt='Clifford J. Bailey'></td><td>Cliff Bailey is Head of Diabetes Research and Professor of Clinical Science at Aston University in Birmingham, England. He is a Fellow of the Royal College of Physicians of Edinburgh and a Fellow of the Royal College of Pathologists. He has been a Royal Society visiting scientist at the University of Southern California, Los Angeles, and a visiting scientist at Hanover Medical School in Germany. He has served on the medical and scientific committee of Diabetes UK (formerly the British Diabetic Association) and was secretary from 1991 to 1994. He has also served on the Society for Endocrinology programme committee and he was a founder member of the European Association for the Study of Diabetes Islet Study Group.<br>Professor Bailey has held various editorial positions, including endocrine section editor of the British Journal of Pharmacology and editorial board member of Diabetes, Obesity and Metabolism. He is presently editor of the British Journal of Diabetes and Vascular Disease and senior editor of Diabetes and Vascular Disease Research. He has been an expert witness for drug licensing authorities, regulatory agencies and other national and international review bodies.  His research is mainly directed towards the pathogenesis and treatment of diabetes, especially the development of new agents to improve insulin action and reduce obesity, and the therapeutic application of surrogate beta-cells.  He has published extensively with over 300 research papers and reviews, and four books.  He also contributes to well-known texts such as the Textbook of Diabetes and the International Textbook of Diabetes Mellitus.</td></tr></table>",
//Array 7 = Holst, Jens Juul
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Jens Juul Holst, MD, PhD</strong><br><i>Professor of Medical Physiology, University of Copenhagen, Denmark</i><br><br></td></tr><tr><td><img src='images/speakers/holst.jpg' alt='Jens Juul Holst'></td><td>Jens Holst is a professor of medical physiology at the University of Copenhagen in Denmark. He is also the vice chairman of the board of the Department of Biomedical Sciences at the University of Copenhagen and chairman of the Faculty's Research Centre for Diabetes and Obesity. He received his medical degree from the University of Copenhagen in 1970 and a Doctor of Medical Sciences degree in 1978.<br><br>Professor Holst's research has been focused on the regulatory peptides of the pancreas and gut. This has included the importance of the peptides in the regulation of the functions of the GI tract and metabolism, with particular focus on blood glucose and appetite regulation, obesity, and diabetes. He has especially conducted research on the role of incretin hormones of the gut (GLP-1 and GIP).<br>Professor Holst has written more than 900 full publications, including original studies, chapters in textbooks, and review articles, and is on the editorial boards of Regulatory Peptides,  Endocrinology and Diabetes. He is a member of several distinguished academic organisations, including the Danish Academy for Natural Sciences and the Royal Danish Academy of Science and Letters, and has been the recipient of the Anders Jahre Award for Medical Research, the Odd Fellow Award for Medical Research, the Paul Langerhans Medal of the German Diabetes Association and the Claude Bernard award of the European Society for the Study of Diabetes.</td></tr></table>",
//Array 8 = Rosenstock, Julio
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Julio Rosenstock, MD</strong><br><i>Director of the Dallas Diabetes and Endocrine Center</i><br><br></td></tr><tr><td><img src='images/speakers/rosenstock.jpg' alt='Julio Rosenstock'></td><td>Julio Rosenstock received his medical degree from the University of Costa Rica School of Medicine. He completed fellowships in Endocrinology and Diabetes at the Royal Postgraduate Medical School at Hammersmith Hospital in London and at the University of Texas Southwestern Medical Center in Dallas. He is board certified in internal medicine and in endocrinology and metabolism. He is currently the Director of the Dallas Diabetes and Endocrine Center, an endocrine practice and clinical research facility. He is also a Clinical Professor of Medicine at the University of Texas Southwestern Medical Center at Dallas. He is actively involved in diabetes education and serves as the representative of The Endocrine Society to NDEP (National Diabetes Education Program sponsored by NIH and CDC).<br><br>Dr Rosenstock's clinical and research activities have focused on exploring novel agents and therapeutic strategies to improve glycaemic control. Over the years, his main interest has been early insulin intervention with combination strategies to reach glycaemic targets in type 2 diabetes. He has developed a special interest and has been actively involved in the development programmes of DPP-4 inhibitors and GLP-1 receptor agonists as a clinical investigator and scientific advisor. <br><br>Dr Rosenstock has more than 230 publications, including peer-reviewed papers and numerous abstracts, and has also contributed to several clinics and book chapters on various topics in the field of diabetes. He is currently an editorial board member of Diabetes Care, Practical Diabetology, Cardiovascular Diabetology and Avances en Diabetologia and is an active reviewer for several journals. He is also a member of numerous professional societies and has chaired or been a featured speaker at multiple lectures and presentations both nationally and internationally.</td></tr></table>",
//Array 9 = Charbonnel, Bernard
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Bernard Charbonnel, MD, PhD</strong><br><i>Director of the Dallas Diabetes and Endocrine Center</i><br><br></td></tr><tr><td><img src='images/speakers/charbonnel.jpg' alt='Bernard Charbonnel'></td><td>Bernard Charbonnel  is Professor of Endocrinology and Metabolic Diseases at the University of Nantes, France, and  Head of the Internal Medicine, Endocrinology and Diabetes Department at the Hotel Dieu (University Hospital of Nantes).<br><br>Professor Charbonnel has previously held the position of Vice President in charge of Research at the University of Nantes from 1987 to 1997, and Chairman of the French Diabetes Guidelines Committee. He is also a past President of the French Diabetes Society (ALFEDIAM).<br>Professor Charbonnel has published more than 300 original and/or review scientific papers, recently including publications such as <i>The Lancet, Diabetes Care, Diabetologia, Diabetic Medicine, The Journal of the American College of Cardiology</i> and <i>The Journal of Endocrinology & Metabolism</i>. He was also a member of the executive committee of the recently published PROactive Study.<br>Professor Charbonnel's main current fields of interest are devoted to clinical research in diabetes, mainly insulin therapy in type 1 and type 2 diabetes, prevention of cardiovascular complications of type 2 diabetes, new treatments of type 2 diabetes and, more generally,  ways of optimising the management of type 2 diabetes.</td></tr></table>",
//Array 10 = Bornstein, Stefan
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Stefan R. Bornstein, MD, PhD</strong><br><i>Professor, Director and Chair of the Department of Medicine, University of Dresden, Germany</i><br><br></td></tr><tr><td><img src='images/speakers/bornstein.jpg' alt='Stefan R. Bornstein'></td><td>Stefan Bornstein attended medical school at the University of Ulm, Germany and the University of Miami, Florida, USA. He received his medical license in 1988 and completed his PhD in 1993. In 1990 undertook research training in the department of Biochemistry at the Southwest Medical Center, University of Texas, USA and was awarded first prize for the new generation of academics in Baden-W&uuml;rtemberg, Germany. From 1994-1997 he held the position of Assistant Professor in the Department of Medicine at the University of Leipzig, Germany and in 1997 he received the Marius Tausk Award from the German Endocrine Society. In 1997 he also became a research scholar and acting Unit Chief for the Endocrine Branch, at the National Institutes of Health in Bethesda, USA. From 2001 to 2004 he was Professor and Vice-chair of the Department of Endocrinology and Metabolism at the University of D&uuml;sseldorf, Germany and during this time he was also scientific coordinator for the NIH State-of-Science conference on clinically inapparent adrenal tumours. Since 2005 he has held the position of Professor, Director and Chair of the Department of Medicine, University of Dresden, Germany.<br>Professor Bornstein has authored or co-authored articles in many publications including, Endocrinology, Diabetes, New England Journal of Medicine, and Endocrine Review.</td></tr></table>",
//Array 11 = Barrett, Eugene
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Eugene J. Barrett, MD, PhD</strong><br><i>Professor of Medicine and Pediatrics and Director of the University of Virginia Diabetes Center and the UVA General Clinical Research Center</i><br><br></td></tr><tr><td><img src='images/speakers/barrett.jpg' alt='Eugene J. Barrett'></td><td>Eugene Barrett received his medical degree and a PhD degree in biophysics from the University of Rochester and subsequently completed sub-speciality training in endocrinology at Yale University.  He joined the Yale faculty and established a research programme examining the action of insulin on skeletal muscle and hepatic glucose and protein metabolism.  He subsequently moved to the University of Virginia, where he is now Professor of Medicine and Pediatrics and Director of the University of Virginia Diabetes Center and the UVA General Clinical Research Center.<br><br>Professor Barrett's laboratory research  is currently focused on dissecting the role of vascular insulin sensitivity/resistance in regulating the metabolic response to insulin in humans and experimental animal systems. The laboratory has identified specific actions of insulin to dilate terminal arterioles within skeletal muscles and thereby enhance tissue perfusion and insulin access to the myocytes.  More recently, the laboratory has demonstrated that insulin travels from the plasma to the interstitium of skeletal muscle via a trans-endothelial transport process that requires insulin to bind to its receptor on the endothelial cell, activate downstream insulin signaling pathways and associate with transporting vesicles (caveolae). Insulin resistance impedes insulin's ability to access the myocyte via this pathway.  Professor Barrett's team have  now begun studies that look at each of the molecular steps involved in moving insulin from the plasma to target cells in muscle, fat, and brain.  He anticipates that understanding these insulin transport processes will allow the unravelling of the molecular aspects of vascular insulin resistance and provide new understanding of the microvascular complications that occur with diabetes.</td></tr></table>",
//Array 12 = Bosi, Emanuele
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Dr Emanuele Bosi, MD, PhD </strong><br><br></td></tr><tr><td><img src='images/speakers/bosi.jpg' alt='Dr Emanuele Bosi'></td><td>Emanuele Bosi graduated in Medicine in 1979 at the University of Milan, Italy, where he further received a speciality diploma in Diabetes and Metabolic Diseases and, subsequently, in Clinical Immunology. During his career he received clinical training in Milan and then worked as clinical investigator at the Edouard Herriot Hospital in Lyon, University College and St. Bartholomew’s Hospitals in London. <br>Dr. Bosi's research activity has been entirely devoted to diabetes, with specific regard to the prediction and prevention of type 1 diabetes and innovative treatments of diabetes, including transplantation, immunotherapy, artificial devices and innovative drugs. He is currently Associate Professor of Endocrinology and Director of the Post-Graduate School of Endocrinology and Metabolic Diseases at the San Raffaele Vita-Salute University, and Head of the Department of Internal Medicine at the San Raffaele Hospital Scientific Institute, Milan, Italy. Dr Bosi is also Principal Investigator and a member of the Steering Committee of the NIH-sponsored Diabetes TrialNet study group and Director of the TrialNet Clinical Center in Italy. He is a leader in clinical investigations and clinical trials on both type 1 and type 2 diabetes and diabetic complications.<br>Dr Bosi has more than 100 scientific publications to his name, in publications such as Diabetes Care, European Journal of Endocrinology and Diabetologia.</td></tr></table>",
//Ab hier Speakers Merck Serono
//Array 13 = Standl, Eberhard
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Dr. Dr. hc. Eberhard Standl</strong><br><i>Munich Diabetes Research Institute at the Munich Helmholtz Center, Munich-Neuherberg, Germany</i><br><br></td></tr><tr><td><img src='images/speakers/standl.jpg' alt='Eberhard Standl'></td><td>Dr. Eberhard Standl is Professor of Medicine, endocrinologist and angiologist at the Munich Diabetes Research Group/Diabetes Research Institute. He graduated from the Universities of Munich and Frankfurt, and has developed his career in both Munich, and at the Joslin Diabetes Center, Boston, USA. He is retired director of the Department of Endocrinology, Diabetology and Metabolism at the Academic Hospital Munich-Schwabing.<br><br>Professor Dr. Standl's principal areas of research are diabetology, micro- and macrovascular disease, cardioneuropathy, action and degradation of insulin, and epidemiology of cardiovascular diabetic complications. He has published some 560 original papers, review articles, textbook chapters and monographs, and has received various scientific awards, including the Bertram Award for research related to vascular disease in diabetes in 1981,  the Castelli-Pedroli Prize of the European Association for the Study of Diabetes (EASD) in 1999, the Harold Rifkin Award of the American Diabetes Association 2005, and the Albert Renold Medal of EASD 2006. He is a member of several scientific associations, with strong affiliations to the German Diabetes Association, the EASD, and the International Diabetes Federation (IDF). He was president of the German Diabetes Association 1988/89, vice-president both of EASD and IDF 2003 to 2006 and chairman of the Organizing Committee for the EASD congress 2004 in Munich. He is vicechair of the newly founded EASD study group on cardiovascular complications, and immediate Past-President both of the German Diabetes Union and  of IDF Europe.<br>Dr. Eberhard Standl is Professor of Medicine, endocrinologist and angiologist at the Munich Diabetes Research Group/Diabetes Research Institute. He graduated from the Universities of Munich and Frankfurt, and has developed his career in both Munich, and at the Joslin Diabetes Center, Boston, USA. He is retired director of the Department of Endocrinology, Diabetology and Metabolism at the Academic Hospital Munich-Schwabing.<br><br>Professor Dr. Standl's principal areas of research are diabetology, micro- and macrovascular disease, cardioneuropathy, action and degradation of insulin, and epidemiology of cardiovascular diabetic complications. He has published some 560 original papers, review articles, textbook chapters and monographs, and has received various scientific awards, including the Bertram Award for research related to vascular disease in diabetes in 1981,  the Castelli-Pedroli Prize of the European Association for the Study of Diabetes (EASD) in 1999, the Harold Rifkin Award of the American Diabetes Association 2005, and the Albert Renold Medal of EASD 2006. He is a member of several scientific associations, with strong affiliations to the German Diabetes Association, the EASD, and the International Diabetes Federation (IDF). He was president of the German Diabetes Association 1988/89, vice-president both of EASD and IDF 2003 to 2006 and chairman of the Organizing Committee for the EASD congress 2004 in Munich. He is vicechair of the newly founded EASD study group on cardiovascular complications, and immediate Past-President both of the German Diabetes Union and  of IDF Europe.</td></tr></table>",
//Array 14 = Ryden, Lars
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Lars Ryden</strong><br><br></td></tr><tr><td><img src='images/speakers/ryden.jpg' alt='Lars Ryden'></td><td>Lars Ryden, Professor Emeritus of Cardiology at the Karolinska Institutet Stockholm Sweden, is a specialist in internal medicine and cardiology. His research focuses on arrhythmias, cardiac pacing, heart failure and cardiovascular disease related to diabetes. Professor Ryden has published over 550 scientific papers in these fields. He is honorary member of the Royal College of Physicians London and of several national cardiac societies.<br><br>Professor Ryden was the President of the Swedish Cardiac Society 1986-1989 and of the European Society of Cardiology (ESC) 1998-2000. He has served on the board of the World Heart Federation and was member of the Nobel Assembly at Karolinska Institutet 1993-2005. During 1995-2004 he chaired the scientific board of the Swedish Heart- and Lung Foundation and 2004-2006 Alert (a system for identification and early assessment concerning new methods in health care) for the Swedish Council on Technology Assessment in Health Care. Professor Ryden co-chaired the task force that prepared the ESC/EASD guidelines for diabetes, prediabetes and cardiovascular disease. Presently he is chairing a group that is working on the implementation of the European Heart Health Charter on behalf of the ESC and European Heart Network.</td></tr></table>",
//Array 15 = Philipp, Jacques
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Jacques Philippe</strong><br><br></td></tr><tr><td><img src='images/speakers/philippe.jpg' alt='Jacques Philippe'></td><td>&nbsp;</td></tr></table>",
//Array 16 = Holman, Rury
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Rury Holman FRCP</strong><br><i>Professor of Diabetic Medicine, Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism </i><br><br></td></tr><tr><td><img src='images/speakers/holman.jpg' alt='Rury Holman'></td><td>Rury Holman was  the  first  Professor  of Diabetic Medicine  to  be  appointed  at  the University  of Oxford. He  is  immediate  past Academic Chairman  of  the Oxford Centre  for Diabetes, Endocrinology  and Metabolism  (OCDEM), Director  of  the University  of Oxford Diabetes  Trials  Unit,  and  an  Honorary  Consultant  Physician  to  the  Oxford  Radcliffe Hospitals NHS Trust.<br><br>Professor Holman divides his time between clinical care of patients, teaching and his many  research  interests.  He  has  designed  and  run  many  multicentre  studies  that  focus primarily on  the prevention, appropriate  treatment and cardiovascular  risk  reduction  type 2 diabetes.  He  has  published over  250  peer-reviewed  manuscripts,  is  Co-chair  of  the NAVIGATOR, TECOS  and DREAM  studies  and Chief  Investigator  of  the  4-T, ACE  and UKPDS trials. </td></tr></table>",
// Ab hier Speakers La Roche
//Array 17 = Ferrannini, Eleuterio
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Eleuterio Ferrannini, MD</strong><br><br></td></tr><tr><td><img src='images/speakers/ferrannini.jpg' alt='Eleuterio Ferrannini'></td><td>Ele Ferrannini is Professor of Internal Medicine at the University of Pisa and Adjunct Clinical Professor at the Diabetes Division, Department of Medicine, University of Texas Health Science Center. After graduating from the University of Pisa, he specialised in Nuclear Medicine and Diabetes and Metabolic Diseases and worked as a postdoctoral fellow at the Fogarty International Center of the National Institutes of Health at Yale University School of Medicine. He is Past-President of the European Association for the Study of Diabetes and currently serves on the Editorial Board for the Journal of Hypertension and the Journal of Clinical Endocrinology & Metabolism. Professor Ferrannini’s fields of expertise are the pathophysiology of hyperglycaemia, insulin resistance and ß-cell function, mathematical modeling of glucose and insulin metabolism, and the clinical course and pathophysiology of cardiovascular complications of diabetes. He has contributed over 400 original papers and 50 book chapters and is on the list (ISIHighlyCited.com) of highly cited scientists.</td></tr></table>",
//Array 18 = Ahren, Bo
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Bo Ahr&eacute;n</strong><br><br></td></tr><tr><td><img src='images/speakers/ahren.jpg' alt='Bo Ahren'></td><td>Bo Ahr&eacute;n, MD, PhD is Professor of Clinical Metabolic Research and Dean of the Faculty of Medicine, Department of Medicine, at Lund University in Lund, Sweden.<br><br>He earned his doctorates in medicine and pharmacology from Lund University, where he also pursued a medical internship at the university's hospital. He then practiced as a physician in Tanzania and Sweden before embarking on a long career in research and teaching at Lund University. His leadership roles there include heading the Medical Research Department (1992-2000) and the Experimental Research Department (1985-1992).<br><br>In his research, Dr. Ahr&eacute;n has concentrated effort on understanding the regulation and mechanism of normal insulin secretion, along with the mechanisms and consequences of failing insulin secretion, as an important pathogenetic factor in diabetes. His studies also aim to develop new targets and compounds for the treatment of type 2 diabetes mellitus (T2DM). Particular emphases have focused on replication of the effects of the incretin hormone GLP-1 and inhibition of dipeptidyl peptidase-4 (DPP-4) as novel treatments of T2DM. This work has resulted in the publication of more than 600 original and review articles in medicine. </td></tr></table>",
//Array 19 = DeFronzo, Ralph Anthony
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Ralph Anthony DeFronzo, MD</strong><br><br></td></tr><tr><td><img src='images/speakers/defronzo.jpg' alt=' Ralph Anthony DeFronzo, MD'></td><td>Ralph A. DeFronzo, MD, is Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center and the Audie L. Murphy Memorial VA Hospital in San Antonio, Texas.  Dr. DeFronzo is a graduate of Harvard Medical School and did his training in Internal Medicine at the Johns Hopkins Hospital. He completed fellowships in endocrinology at the National Institutes of Health and Baltimore City Hospitals and in Nephrology at the Hospital of the University of Pennsylvania.  Subsequently, he joined the faculty at the Yale University School of Medicine (1975-88) as an Assistant/Associate Professor.<br>His major interests focus on the pathogenesis and treatment of type 2 diabetes mellitus and the central role of insulin resistance in the metabolic-cardiovascular cluster of disorders known collectively as the Insulin Resistance Syndrome.  Using the euglycemic insulin clamp technique in combination with radioisotope turnover methodology, limb catheterization, indirect calorimetry, and muscle biopsy, he has helped to define the biochemical and molecular disturbances responsible for insulin resistance in type 2 diabetes mellitus.<br><br>For his work in this area, Dr. DeFronzo received the prestigious Lilly Award (1987) by the American Diabetes Association (ADA), the Banting Lectureship (1988) by the Canadian Diabetes Association, the Novartis Award (2003) for outstanding clinical investigation world wide and many other national and international awards. He also is the recipient of the ADA's Albert Renold Award (2002) for lifetime commitment to the training of young diabetes investigators.  Dr. DeFronzo received the Banting Award from the ADA (2008) and the Claude Bernard Award from the EASD (2008).  These represent the highest scientific achievement awards given by the American and European Diabetes Associations, respectively. In 2008 Dr. DeFronzo also received the Italian Diabetes Mentor Prize and the Philip Bondy Lecture at Yale. With more than 500 articles published in peer-reviewed medical journals, Dr. DeFronzo is a distinguished clinician, teacher, and investigator who has been an invited speaker at major national and international conferences on diabetes mellitus.</td></tr></table>",
// Ab hier Speakers Novartis
//Array 20 = Bolli, Geremia
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Geremia B. Bolli</strong><br><br></td></tr><tr><td><img src='images/speakers/bolli.jpg' alt='Geremia Bolli'></td><td>Prof. Geremia Bolli graduated from the Perugia University School of Medicine in 1972.  After training in Cardiology and Internal Medicine at the Pisa and Perugia University Schools of Medicine, respectively, Prof. Bolli trained in Endocrinology at Mayo Clinic betewen in 1982-83 under the guidance of Dr. John E. Gerich.  After he went back to University of Perugia where he currently is Professor of Medicine and director of the internal medicine and diabetes clinic.<br><br>Prof. Bolli has served in scientific societies (Honorary Secretary and Vice-President of the European Society for Clinical Investigation, Associate and Deputy-in-Chief Editor for Diabetologia), he is currently member of several societies, including the European Association for the Study of Diabetes and American Diabetes Association.  Prof. Bolli has been awarded with the Morgagni Prize, University of Padova, 1985; the BCL Award, British Association of Clinical Biochemists, Glasgow, 1986; Camillo Golgi Prize, European Association for the Study of Diabetes. Lisbon, 1989; Mary Jane Kugel Award, Juvenile Diabetes Foundation International, New York, 1999; Novartis Award in Diabetes for Long-standing Achievement, Philadelphia, 2001; Paulescu Prize, International Diabetes Federation, Paris, 2003; and the Somogyi Award, Hungarian Diabetes Association, Hungary, 2006.<br><br>Prof. Bolli's interest in research has initially been methodology and clinical significance of measurement of glycosylated haemoglobin, and later physiology of glucose counterregulation to hypoglycaemia and pathophysiology of hypoglycaemia in Type 1 and Type 2 diabetes mellitus.  At the same time, he has studied pharmacokinetics and pharmacodynamics of insulin preparations, including rapid- and long-acting insulin analogues, and set up models of intensive insulin therapy for treatment of Type 1 and Type 2 diabetes mellitus.  The present interest of Prof. Bolli is long-term optimization of glycaemic control in Type 1 and Type 2 diabetes mellitus.  In Type 1, Prof. Bolli is currently developing strategies to near-normalize blood glucose along with identification, treatment and prevention of hypoglycaemia and hypoglycaemia unawareness.  In Type 2 diabetes, Prof. Bolli is engaged with use of insulin in an early phase of disease. Prof. Bolli is author of 351 scientific publications in peer-reviewed journals and book chapters (excluding abstracts).</td></tr></table>",
//Array 21 = Fonseca, Vivian
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Vivian A. Fonseca, MD, FRCP</strong><br><i>Tullis-Tulane Alumni Chair in Diabetes, Professor of Medicine and Chief of the Section of Endocrinology, Tulane University Medical Center, New Orleans, USA <br>Scott and White Healthcare and Texas A & M College of Medicine, USA</i><br><br><br></td></tr><tr><td><img src='images/speakers/fonseca.jpg' alt='Vivian A. Fonseca'></td><td>Vivian A. Fonseca, MD, FRCP, is Professor of Medicine, the Tullis-Tulane Alumni Chair in Diabetes, and chief of the Section of Endocrinology at Tulane University Medical Center in New Orleans, Louisiana. He is also in transition as Professor of Medicine and Chief of the Division of Endocrinology at Scott and White Healthcare and Texas A & M College of Medicine, Temple and Round Rock, TX<br><br>He is Editor in chief of Diabetes Care since 2007, having formerly been associate editor. He was until 2006 Editor in Chief of the Journal of the Metabolic Syndrome and related disorders. He served on the editorial board of the Journal of Clinical Endocrinology and Metabolism (2003-2006). He is an ad hoc reviewer for several other journals, including New England Journal of Medicine, JAMA, Diabetes, Diabetic Medicine, Kidney International, the American Journal of Clinical Nutrition, the British Medical Journal, and Metabolism. <br><br>Dr. Fonseca has served on the clinical practice committee of the American Diabetes Association (chairman 2003-05) and the joint ADA/ACC 'Make the Link' Program.<br><br>Dr. Fonseca is a fellow of the American Association of Clinical Endocrinologists, the Royal College of Physicians (London), and the American College of Physicians. He is a member of the Endocrine Society, the American Diabetes Association, and the International Diabetes Federation.  He serves on several national and international committees, and has published over 200 papers, review articles and book chapters. <br><br>Dr. Fonseca's current research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease. He has a research program evaluating homocysteine and inflammation as risk factors for heart disease in diabetes. He is also an investigator in the NIH-funded Action to Control Cardiovascular Risk in Diabetes (ACCORD) study and serves on the Glycemia control committee. He is a co- Investigator on the NIH TINSAL-2D study and serves on the Steering and Ancillary studies committees. He is funded by the American Diabetes Association to study 'The impact of hurricane Katrina on diabetes and co-morbidities'.  Dr. Fonseca has lectured in the United States and abroad. He is the editor of the text book 'Clinical Diabetes: Translating Research into Practice' (El Sevier 2006) and several monographs and book chapters.</td></tr></table>",
//Array 22 = Schmidt, Wolfgang
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Wolfgang E. Schmidt</strong><br><i>Bochum, Germany</i><br><br></td></tr><tr><td><img src='images/speakers/schmidt.jpg' alt='Wolfgang E. Schmidt'></td><td>Wolfgang Schmidt is Chair and Professor of Internal Medicine at the Ruhr-University of Bochum School of Medicine and Director of the Department of Medicine I at the university's St. Josef Hospital. Professor Schmidt's major clinical areas of expertise are wide-ranging and include gastroenterology, diabetology, hepatology, gastrointestinal (GI) endocrinology, GI oncology and general internal medicine. His major research areas are the enteroinsular axis, incretins, regulatory gut brain peptides, type 2 diabetes (pathophysiology and novel therapeutic strategies), pancreatitis and GI malignancies. Professor Schmidt has published over 280 peer-reviewed articles, 30 book chapters and reviews and more than 300 abstracts. He has been the Editor-in-Chief of Regulatory Peptides for 10 years and has received 17 scientific awards and honours.</td></tr></table>",
//Ab hier Speakers Novo Nordisk
//Array 23 = Ludvik, Bernhard
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Bernhard Ludvik</strong><br><i>Vienna, Austria</i><br><br></td></tr><tr><td>&nbsp;</td><td>Bernhard Ludvik is Associate Professor of Medicine at the Medical University of Vienna, where he is also Leader of the working group on obesity and endocrinology, attending in internal medicine and endocrinology, as well as Vice-chairman of the endocrinology and metabolism division. Additionally, Professor Ludvik has been President of the Austrian Diabetes Association since 2008 and is a member of several publication advisory and editorial boards. His research focuses on pathogenesis and therapy of type 2 diabetes, the metabolic syndrome and obesity, migration and application of telemedicine technologies in diabetology. He has published over 100 articles in peer-reviewed journals and has participated as a principal investigator of numerous studies and clinical trials in phases 1, 2 and 3 on the treatment of obesity, diabetes and lipid metabolic disorders.</td></tr></table>",
//Array 24 = Tuomilehto, Jaakko
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Jaakko Tuomilehto</strong><br><i>Helsinki, Finland</i><br><br></td></tr><tr><td>&nbsp;</td><td>Jaakko Tuomilehto is currently Professor of Public Health, University of Helsinki, Finland and Adjunct Research Professor at the Washington State University, Center for International Health Services Research and Policy, Spokane, USA. He has been involved in a number of key diabetes and cardiovascular prevention studies, including the Finnish Diabetes Prevention Study, the WHO's MONICA project ( Multinational MONItoring of trends and determinants in Cardiovascular disease). Professor Tuomilehto has extensive experience in clinical studies: he has been recruited as principal investigator in c. 30 over the last 35 years. He has published over 1100 peer-reviewed original articles and over 300 editorials, reviews and book chapters as well as serving on many scientific journal advisory boards.</td></tr></table>",
//Array 25 = Nattrass, Malcom
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Malcolm Nattrass</strong><br><i>Birmingham, UK</i><br><br></td></tr><tr><td>&nbsp;</td><td>Malcolm Nattrass is a Fellow of the Royal College of Physicians of London and a Fellow of the Royal College of Pathologists. Dr Nattrass has published extensively in the areas of diabetic ketoacidosis, myocardial infarction in diabetes, and treatment of type 2 diabetes with oral agents. In addition to original publications he has written many reviews and is the sole author of the diabetes textbook Malins' Clinical Diabetes.</td></tr></table>",
//Array 26 = Meier, Juris
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Juris Meier</strong><br><i>Bochum, Germany</i><br><br></td></tr><tr><td><img src='images/speakers/meier.jpg'></td><td>Juris Meier is Assistant Professor in the Department of Medicine I at St. Josef-Hospital, which is part of the Ruhr-University. He has received numerous national and international scientific awards, including the Rising Star Lecture Award from the European Diabetes Association (EASD).<br><br>Professor Meier's research interests include the regulation of insulin secretion in vivo, the physiological actions and therapeutic applications of incretin hormones, and the mechanisms of beta-cell death in patients with diabetes. He has authored and co-authored over 80 publications in peer-reviewed journals and serves as the Associate Editor of Regulatory Peptides and is a member of the editorial board of Diabetes</td></tr></table>",
//Array 27 = Buse, John
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>John B. Buse</strong><br><i>Chapel Hill, NC, USA</i><br><br></td></tr><tr><td>&nbsp;</td><td>John Buse is Professor at the University of North Carolina School of Medicine in Chapel Hill, NC, USA where he serves as Director of the Diabetes Care Center, Chief of the Division of Endocrinology and Executive Associate Dean for Clinical Research. Professor Buse has a diabetes practice located at UNC as well as at the Salem Center in Winston-Salem, NC. His research interests focus on developing prevention and treatment strategies for diabetes type 1 and 2 and their complications. He has authored more than 200 publications and is involved in numerous multicentre clinical trials, most prominently the National Heart Lung and Blood Institute's ACCORD (Action to Control Cardiovascular Risk in Diabetes) study. Dr Buse has just completed service as President for Medicine and Science at the American Diabetes Association (ADA).</td></tr></table>",
//Array 28 = Nauck, Michael
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Michael Nauck</strong><br><i>Bad Lauterberg, Germany</i><br><br>Michael Nauck is Professor and Head Physician at the Diabeteszentrum, Bad Lauterberg in Germany. Professor Nauck maintains an active clinical practice, as well as a productive research programme. Among his areas of scientific interest are the role and impact of gastrointestinal peptide (incretin) hormones, namely glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide. He has contributed to the development of new therapies for type 2-diabetes based on the antidiabetic properties of these incretin hormones and related incretin mimetics. His other interests are spontaneous hypoglycaemia, pancreas transplantation, and cardiovascular disease in type 2-diabetes. Professor Nauck was awarded the Ferdinand-Bertram and the Werner-Creutzfeldt-Awards from the Deutsche Diabetes-Gesellschaft (DDG) in 1993 and 2007.</td></tr></table>",
//Array 29 = Vora, Jiten
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Jiten Vora</strong><br><i>Liverpool, UK </i><br><br>Jiten Vora is consultant physician at the Royal Liverpool University Hospital and honorary Professor at the University of Liverpool. Professor Vora has on-going research interests in the development of/ screening for/ treatment of diabetic retinopathy; renal haemodynamics/function and hypertension in Type 2 diabetes, the prevention of renal disease in diabetes and the physiological aspects of treatment of Type 2 diabetes. He has published extensively in these fields. Professor Vora has served on many advisory panels, the National Institute for Clinical Excellence and the Diabetes and Renal National Service Frameworks.</td></tr></table>",
//Array 30 = Davidson, Michael
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Michael H. Davidson</strong><br><i>Chicago, IL, USA</i><br><br>Michael H. Davidson is a Clinical Professor at the University of Chicago, where he also serves as Director of Preventive Cardiology and Associate Vice Chairman for Continuing Medical Education. In addition, he is Founder, President, and Chief Executive Officer of the Chicago Centre for Clinical Research, currently part of Radiant Research. Professor Davidson's extensive research on statins, novel lipid-lowering drugs, and non-pharmacological risk factor reduction has established him as a key opinion leader in this area. His research also includes extensive work with food additives, dietary supplements, and health claim petitions to the US Food and Drug Administration (FDA).</td></tr></table>",
//Array 31 = Gough, Stephen
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Stephen Gough</strong><br><i>Birmingham, UK</i><br><br></td></tr><tr><td><img src='images/speakers/gough.jpg'></td><td>Stephen Gough is Professor of Medicine at the University of Birmingham and Consultant Physician with a special interest in diabetes at University Hospital Birmingham NHS Foundation Trust. As part of his role at the university, Professor Gough leads an active diabetes research group with regular peer-reviewed publications. His research interests include genetics of autoimmunity and he is a member of the UK National Wellcome Trust Case Control Consortium (WTCCC) for genetic studies in common disease. Other research includes monitoring of glycaemic control, stress hyperglycaemia, community screening for diabetes, and the link between diabetes and schizophrenia.</td></tr></table>", 
//Array 32 = Mathieu, Chantal
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Chantal Mathieu</strong><br><i>Leuven, Belgium</i><br><br></td></tr><tr><td>&nbsp;</td><td>Chantal Mathieu is Professor of Medicine, Katholieke Universiteit Leuven and Head of Endocrinology, University Hospital Gasthuisberg, Leuven, Belgium. She is a clinical researcher for the Flemish Research Council and her research activities include the study of the pathogenesis of type 1 diabetes, disease prevention and islet transplantation in animal models, and understanding the potential role of vitamin D in the process. Professor Mathieu's group has recently participated in translational studies of disease prevention and islet transplantation in humans. She has published over 250 papers in international journals and is an advisor to Diabetologia, past President of the Flemish Diabetes Society and a member of IPITA, ADA, TES, IDS, BES and EASD. Professor Mathieu has received several awards, including the 9th International Workshop on Vitamin D Young Investigators Travel Award, Belgium Menarini prijs voor diabetologie, the Belgian Endocrine Society Award, and the Belgian Endocrine Society Young Investigator Travel Award.</td></tr></table>",
//Array 33 = Marx, Niko
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Nikolaus Marx</strong><br><i>Ulm, Germany</i><br><br></td></tr><tr><td>&nbsp;</td><td>Nikolaus Marx is Professor of Medicine at the University of Ulm in Germany. He received his medical training at the Universities of Mainz, Geneva and D&uuml;sseldorf. Professor Marx is a member of several organisations within the field of diabetes and the vasculature, including the ESC, AHA and the EASD. In addition to reviewing submitted manuscripts for numerous journals, including Circulation, Diabetologia, Diabetes, Diabetes Care, the Journal of Immunology and The Lancet, he is currently Associate Editor for Diabetes and Vascular Disease Research. Professor Marx has received several awards in his career so far, including the EASD's Rising Star Award 2005.</td></tr></table>",
//Array 34 = Heller, Simon
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Simon Heller</strong><br>Sheffield, UK<br><br></td></tr><tr><td><img src='images/speakers/heller.jpg' alt='Simon Heller'></td><td>Simon Heller is Professor of Clinical Diabetes at the University of Sheffield, and Director of Research and Development and Honorary Consultant Physician at Sheffield Teaching Hospitals Foundation Trust. His current research interests include the physiological responses to hypoglycaemia and hypoglycaemia unawareness, pathophysiological mechanisms of sudden death in type 1 diabetes and developing interventions to encourage more effective diabetes self-management. He was a co-investigator, member of the management committee and Chair of the glucose control group in the world's largest diabetes trial, the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE study), which investigated practical treatment strategies to prevent vascular complications of diabetes.</td></tr></table>",
//Array 35 = Christiansen, Christiansen
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Jens Sandahl Christiansen</strong><br><br></td></tr><tr><td>&nbsp;</td><td>Jens Sandahl Christiansen is Professor of Endocrinology and Diabetology, and Consultant Endocrinologist at Aarhus University Hospital. He chairs the hospital's good clinical practice unit and is active in organising and evaluating diabetes care. With interests including growth hormone physiology, diabetic kidney disease, continuous glucose monitoring and insulin absorption, Professor Christiansen has conducted many studies and clinical research projects, and has published more than 500 articles. He is currently Editor of Growth Hormone & IGF Research, and is involved in numerous endocrinology and diabetes organisations. Professor Christiansen has lectured extensively on diabetes and growth hormone replacement therapy and has received several prestigious awards for his work in endocrinology.</td></tr></table>", 
//Array 36 = Blonde, Lawrence
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Lawrence Blonde, New Orleans, LA, USA</strong><br><br></td></tr><tr><td><img src='images/speakers/blonde.jpg'></td><td>Lawrence Blonde is Director of the Ochsner Diabetes Clinical Research Unit in the Department of Endocrinology, Diabetes and Metabolism, and an Associate Internal Medicine Residency Program Director at the Ochsner Medical Center in New Orleans, Louisiana. Dr Blonde is the immediate past Chair of the Steering Committee of the National Diabetes Education Program, a partnership of the National Institutes of Health, the Centers for Disease Control and Prevention, and more than 200 organisations working to change the way diabetes is treated. He has served on the National Quality Forum Adult Diabetes Care Consensus Maintenance Committee, the American Diabetes Association (ADA) Board of Directors, the ADA Doing Better Committee, and the ADA Professional Practice Committee, which develops practice guidelines for the care of people with diabetes.</td></tr></table>",
//Array 37 = Owens, David
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>David R Owens, CBE</strong><br><br></td></tr><tr><td><img src='images/speakers/owens.jpg'></td><td>David R Owens is Director of the Diabetes Research Unit at University Hospital Llandough in Cardiff, where he runs a clinical investigations unit with emphasis on the research into new therapies for diabetes care.  He has been actively involved in the management and research into diabetes for more than 30 years.  He was the first Director and Clinical Lead for the Diabetic Retinopathy Screening Service for Wales, which was established in 2002 and is the Lead for the Diabetes Research Network in Wales.  Additionally, Professor Owens is the Director of the Post-graduate Diploma in Diabetes, an on-line course validated by Cardiff University.<br><br>Professor Owens has an active interest in the role of SMBG in diabetes.  He has produced a variety of published material and has given lectures internationally on this subject.  He is Chair of the International Working Group on SMBG and is involved as an author in the preparation of a consensus guideline on behalf of the IDF.<br><br>Professor Owens is renowned as a key opinion leader and is regularly invited to participate at major international meetings and advisory boards.  He has published extensively with over 250 journal articles, book chapters, etc.  In 2003 he was honoured with the CBE award by the Queen, for his services to medicine.</td></tr></table>",
//Array 38 = Reach, Gerard
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>G&eacute;rard Reach, MD, FRCP Edin</strong><br><i>Professor of Endocrinology and Metabolic Diseases</i><br><br></td></tr><tr><td><img src='images/speakers/reach.jpg'></td><td><p>G&eacute;rard Reach is Professor of Endocrinology and Metabolism at University Paris and Head of the Department of Endocrinology, Diabetes and Metabolic Diseases at Avicenne Hospital at the University of Paris 13 in Bobigny after serving over 10 years as Director of the INSERM Research Unit on Biomedical Engineering and Diabetes, H&ocirc;tel-Dieu Hospital in Paris , France . </p><p>He has published extensively with over 217 papers and 72 chapters, 178 papers being indexed in PubMed . He is the author of two books (in French) on Adherence to therapy in chronic diseases with a third book submitted. </p><p>He served as President of the Society for <em>Artificial Insulin Delivery, Pancreas and Islet Transplantation </em> (AIDPIT) study group of the EASD after being its organizing Secretary and as Editor-in-Chief for the Journal <em>Diabetes &amp; Metabolism </em>. </p><p>Professor Reach received several acknowledged scientific awards; Jacques Mirouze Award of the French National Academy of Medicine (1997), International Society of Blood Purification Annual Award (1996), Pierre Roman&ccedil;on Award of the Foundation for Medical Research (1994), and the Apollinaire Bouchardat Award (1987). </p></td></tr></table>",
//Array 39 = Polonsky, William
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>William H Polonsky, PhD, CDE</strong><br><br></td></tr><tr><td><img src='images/speakers/polonsky.jpg'></td><td><p>William H. Polonsky is Associate Clinical Professor in Psychiatry at the University of California , San Diego . As licensed psychologist and certified diabetes educator, he is the author of Diabetes Burnout: What to Do When You Can't Take It Anymore and the co-author of The Secrets of Living and Loving with Diabetes . He is the founder of the Behavioral Diabetes Institute ( <a href=http://www.behavioraldiabetes.org/ target=blank>www.behavioraldiabetes.org </a> ), the world's first organization dedicated to addressing the unmet psychological needs of people with diabetes. </p><p>Professor Polonsky received his PhD in clinical psychology from Yale University and has served as Chairman of the National Certification Board for Diabetes Educators, Senior Psychologist at the Joslin Diabetes Center in Boston and Instructor in Psychiatry at Harvard Medical School . Professor Polonsky has served on the editorial boards of numerous lay and professional journals in diabetes, including Diabetes Care, Clinical Diabetes, Diabetes Forecast, Diabetes Self-Management and Diabetes Health. </p><p>Professor Polonsky has published and lectured widely on diabetes burnout and strategies for securing supportive environments for people with diabetes. He is an active researcher in behavioral diabetes, with his most recent projects focusing on the utility of home blood glucose monitoring for people with type 2 diabetes, the emotional and behavioral consequences of being diagnosed with diabetes, and the value of diabetes self-management support training for health care professionals. </p></td></tr></table>",
//Array 40 = Fisher, Lawrence
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Lawrence Fisher, Ph.D.</strong><br><br></td></tr><tr><td><img src='images/speakers/fisher.jpg'></td><td><p>Dr. Fisher is a licensed Clinical Psychologist in San Francisco , California and a Professor in the Departments of Family &amp; Community Medicine and Psychiatry at the University of California , San Francisco in USA . He is the author of over 120 papers published in peer reviewed journals and is currently an Associate Editor of Diabetes Care. </p><p>Dr. Fisher has been the principal investigator of several National Institute of Health (NIH) - funded research programs of research that addressed the personal, cultural, family and care-related aspects of diabetes self-management. He has also been the principal investigator of several NIH- and ADA-funded longitudinal studies to assess factors associated with depression and distress among patients with diabetes, and on interventions to improve the collaborative family management of diabetes and to reduce diabetes distress and burnout over time. </p><p>Dr. Fisher is also an investigator on two NIH-funded studies to assist primary care practices to improve the care of patients with diabetes. Since 2001, he has won two major teaching awards from the University of California, San Francisco (UCSF) School of Medicine, was nominated for the UCSF Postdoctoral Scholars Association Outstanding Mentorship Award, and has received a certificate from the American Psychological Association in &quot;Recognition for Substantial Contributions to the Field of Family Psychology and Health. </p></td></tr></table>",
//Array 41 = Kerr, David
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Dr David Kerr DM FRCP, FRCPE</strong><br><br></td></tr><tr><td><img src='images/speakers/kerr.jpg'></td><td><p>Since 1993, Dr David Kerr MD FRCPE is Consultant Physician in General Medicine and Diabetes at the Bournemouth Diabetes and Endocrine Centre <a href=http://www.b-dec.co.uk target=_blank>(www.b-dec.co.uk) </a> in the Royal Bournemouth Hospital , Bournemouth , UK . He is also Honorary Senior Lecturer at the University of Southampton and Visiting professor at the Bournemouth University . As part of this latter position he is the lead member for clinical research at the newly established Post Graduate Medical Research and Education Centre. </p><p>In one of his previous positions Dr. Kerr worked in the Division of Endocrinology, School of Medicine at the Yale University in New Haven , USA . </p><p>As well as providing clinical service in Internal Medicine and Diabetes, Dr Kerr runs one of the largest insulin and glucose sensor programmes in the UK . His research interests include the use of technologies in diabetes care, the problem of hypoglycaemia and the prevention of obesity in children and adolescents. Dr Kerr is a co-founder of the Diabetes Inpatient National Network which was established in 2007, and is also Editor of Diabetes Digest.</p></td></tr></table>",
//Array 42 = Home, Philip
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Philip Home, MA, DPhil, DM, FRCP</strong><br><i>University of Newcastle, Newcastle, UK</i><br><br></td></tr><tr><td><img src='images/speakers/home.jpg'></td><td>Philip Home is Professor of Diabetes Medicine at Newcastle University, and Consultant Physician in Diabetes and Metabolic Medicine at Newcastle Hospitals NHS Trust / Newcastle Primary Care Trust. Professor Home is vice-Chair of the National Institute of Clinical Excellence (NICE) Appraisal Committee, the UK drug reimbursement advisory committee, and has been Clinical Lead to UK (NICE) and International Diabetes Federation (IDF) clinical guidelines for diabetes. He was previously President of IDF Europe and Vice-President of the IDF and is the Programme Committee Lead for the next IDF World Diabetes Congress. His major research interest is new therapies for diabetes management, both insulin and oral agents, and he has published extensively in these and related areas.</td></tr></table>",
//Array 43 = Davies, Melanie
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Melanie Davies, MB ChB, MD, FRCP</strong><br><i>University Hospitals of Leicester NHS Trust</i><br><br></td></tr><tr><td><img src='images/speakers/davies.jpg'></td><td>Melanie Davies is an Honorary Consultant Physician in the University Hospitals of Leicester NHS Trust and, since February 2006, Professor of Diabetes Medicine at the University of Leicester. She trained in Sheffield and then completed her training in Cambridge, Ipswich and Leicester. Much of her work has been related to beta-cell dysfunction in T2DM, impaired glucose tolerance, and screening and prevention of T2DM. Professor Davies has been actively involved in the work of Diabetes UK, the National Service Framework (Prevention and Early Detection of T2DM), the Department of Health (Review for Diabetes Research in the UK), and National Institute of Clinical Excellence (NICE guidelines for T1DM and T2DM). She has Global and National Principal Investigator roles for many large international clinical trials in the field of diabetes and is the National Lead for the DESMOND Collaborative in the UK, which has conducted one of the largest RCTs on structured education in T2DM.</td></tr></table>",
//Array 44 = Porcellati, Francesca
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Francesca Porcellati, MD, PhD</strong><br><i>University of Perugia, Perugia, Italy</i><br><br></td></tr><tr><td><img src='images/speakers/porcellati.jpg'></td><td>Francesca Porcellati is Assistant Professor in the Department of Internal Medicine, Endocrinology and Metabolism at the University of Perugia, Perugia, Italy. Professor Porcellati received her MD and PhD from the University of Pergugia and went on to complete specialist training in endocrinology and metabolism and conduct clinical research. Her research interests include the clinical pharmacology of insulin therapies, particularly insulin analogues. </td></tr></table>",
//Array 45 = Leahy, John
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>John L. Leahy, MD</strong><br><i>University of Vermont College of Medicine, Burlington, Vermont, USA</i><br><br></td></tr><tr><td><img src='images/speakers/leahy.jpg'></td><td>John L. Leahy is Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at the University of Vermont College of Medicine, Burlington. He is Director of the Vermont Regional Diabetes Center and Attending Physician at the Medicine Health Care Service. Professor Leahy's current research activities are focused on beta-cell function and insulin resistance. He has authored and co-authored many book chapters and articles in peer-reviewed journals such as Diabetes, and the New England Journal of Medicine. He currently is co-editor of Year Book of Endocrinology and was Editor-in-Chief of Insulin Therapy and Your Practice: Strategies for Improving Patient Outcomes, published by the ADA. He is a member of the ADA, the American Society of Clinical Investigation, the EASD, and the Endocrine Society, and has served on various committees for these and other professional societies. He has received numerous awards for his research and teaching activities.</td></tr></table>",
//Array 46 = Herman, William
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>William H. Herman, MD, MPH</strong><br><i>University of Michigan, Michigan, USA</i><br><br></td></tr><tr><td><img src='images/speakers/herman.jpg'></td><td>William H. Herman is Professor of Medicine and Epidemiology at the University of Michigan and Director of the Michigan Diabetes Research and Training Center. He completed his undergraduate degree at Yale College in 1975, and received his medical degree from Boston University in 1979. He gained a Masters of Public Health (Epidemiology) from the University of Michigan in 1993. Professor Herman's interests include clinical diabetes and diabetes epidemiology, especially in the areas of surveillance, screening, treatment, and cost-effectiveness analysis. He has authored more the 200 original research papers, reviews and textbook chapters and is a member of the research groups for the Diabetes Control Complications Trial (DCCT), Epidemiology of Diabetes Interventions and Complications (EDIC), Diabetes Prevention Program (DPP), and Translating Research In Action for Diabetes (TRIAD). Professor Herman received the American Diabetes Association's Kelly West Award for outstanding achievement in diabetes epidemiology in 2006.</td></tr></table>",
//Array 47 = Van Gaal, Luc
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Luc Van Gaal, MD</strong><br><i>Antwerp University Hospital, Antwerp, Belgium</i><br><br></td></tr><tr><td><img src='images/speakers/vangaal.jpg'></td><td>William H. Herman is Professor of Medicine and Epidemiology at the University of Michigan and Director of the Michigan Diabetes Research and Training Center. He completed his undergraduate degree at Yale College in 1975, and received his medical degree from Boston University in 1979. He gained a Masters of Public Health (Epidemiology) from the University of Michigan in 1993. Professor Herman's interests include clinical diabetes and diabetes epidemiology, especially in the areas of surveillance, screening, treatment, and cost-effectiveness analysis. He has authored more the 200 original research papers, reviews and textbook chapters and is a member of the research groups for the Diabetes Control Complications Trial (DCCT), Epidemiology of Diabetes Interventions and Complications (EDIC), Diabetes Prevention Program (DPP), and Translating Research In Action for Diabetes (TRIAD). Professor Herman received the American Diabetes Association's Kelly West Award for outstanding achievement in diabetes epidemiology in 2006.</td></tr></table>",
//Array 48 = Garg, Satish
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Satish K. Garg, MD, MBBS, DM</strong><br><i>University of Colorado Health Sciences Center, Denver, USA</i><br><br></td></tr><tr><td><img src='images/speakers/garg.jpg'></td><td>Satish K. Garg is Professor of Medicine and Pediatrics at the Young Adult Clinic of the Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Denver, Colorado. His research interests include the early detection and treatment of renal and retinal complications of diabetes, and the development of new diagnostic and therapeutic tools related to clinical diabetes management, including new insulin analogues and glucose sensors. Professor Garg is Editor-in-Chief of Diabetes Technology and Therapeutics Journal. and serves on the editorial boards of several international diabetes journals. He is a member of many medical associations, including the IDF, ADA, EASD, the Endocrine Society of India, the Research Society for Study of Diabetes Mellitus, and numerous other professional societies in both the United States and India. Professor Garg is an international speaker, and has published many book chapters and more than 165 original manuscripts in peer-reviewed journals.</td></tr></table>",
//Array 49 = Ritzel, Robert
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Robert A. Ritzel</strong><br><i>University of Heidelberg, Germany</i><br><br></td></tr><tr><td><img src='images/speakers/ritzel.jpg'></td><td>Robert A. Ritzel is a Consultant / Senior Physician in the Department of Internal Medicine I, Division of Endocrinology and Diabetes, University of Heidelberg, Germany. He received his medical training at Johann Wolfgang Goethe-University, Frankfurt a.M., Georg August-University G&ouml;ttingen, and Ruhr-University Bochum, Germany. He is board certified in internal medicine and in endocrinology and diabetes. Over the past 15 years, Dr Ritzel has been actively involved in research into many aspects of diabetes and has conducted research at centres in Germany and in the USA. His research interests include the pathophysiology of insulin secretion, islet biology and beta-cell apoptosis for which he has been awarded numerous awards.</td></tr></table>",
//Array 50 = Chen, Harn-Shen
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Harn-Shen Chen, MD, PhD</strong><br><i>National Yang-Ming University School of Medicine, Taipei, Taiwan</i><br><br></td></tr><tr><td><img src='images/speakers/chen.jpg'></td><td>Harn-Shen Chen is Associate Professor of Medicine in the Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan. Professor Chen is also Attending Physician in the Division of Endocrinology and Metabolism at Taipei Veterans General Hospital, Taiwan. He was awarded his medical degree from the China Medical University, Taichung, Taiwan and his PhD from the Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. Professor Chen’s research interests include the effects of insulin on beta-cell preservation.</td></tr></table>",
//Array 51 = Alvarsson, Michael
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Michael Alvarsson, MD, PhD</strong><br><i>Karolinska University Hospital Solna, Stockholm, Sweden</i><br><br></td></tr><tr><td><img src='images/speakers/alvarsson.jpg'></td><td>Michael Alvarsson is Medical Director for the Diabetes Section in the Department of Endocrinology, Metabolism and Diabetes at the Karolinska University Hospital Solna, Stockholm, Sweden. He is the Scientific Secretary of the Swedish Society of Diabetology. He wrote his thesis at the Karolinska Institute on the topic of low insulin secretion as a risk factor for T2DM. His research since then has focused on the pathogenesis of T2DM, and clinically his main interest is insulin treatment of T2DM.</td></tr></table>",
//Array 52 = Skyler, Jay
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Jay Sklyer</strong><br><i>University of Miami Leonard M. Miller School of Medicine, Miami, USA</i><br><br></td></tr><tr><td><img src='images/speakers/skyler.jpg'></td><td>Jay S. Skyler is Professor of Medicine, Pediatrics, and Psychology at the University of Miami Leonard M. Miller School of Medicine, Associate Director for Academic Programs at the Diabetes Research Institute, and Chairman of the NIH (NIDDK)-sponsored T1DM TrialNet. His research interests are in clinical aspects of diabetes, particularly improving the care of T1DM. Professor Skyler is a Master of the American College of Physicians and has been closely involved with many scientific societies including the ADA and the IDF. Professor Skyler serves on the editorial boards of numerous journals, was Founding Editor of <em>Diabetes Care, </em>and is currently Associate Editor of <em>Diabetes Technology &amp; Therapeutics </em>, Advisory Editor of <em>Diabetologia </em>, and Scientific Editor of the <em>International Diabetes Monitor </em>. Professor Skyler has published more than 450 articles on diabetes and related areas.</td></tr></table>",
//Ab hier Speakers Takeda & Ely Lilly
//Array 53 = Betteridge, John
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>D John Betteridge, BSc, MB BS, PhD, MD, FRCP, FAHA</strong><br><i>Professor of Endocrinology and Metabolism, Department of Medicine, University College London, UK and Consultant Physician, University College Hospitals, London, UK</i><br><br></td></tr><tr><td><img src='images/speakers/betteridge.jpg'></td><td>Professor Betteridge is a past Chairman of the British Hyperlipidaemia Association (now HEART UK) and past President of the Council on Lipids in Clinical Medicine at The Royal Society of Medicine. He is a committee member of the European Chapter and an elected Distinguished Fellow of the International Atherosclerosis Society. He is a Fellow of the American Heart Association and a member of numerous international bodies, including the European and American Diabetes Associations and the European Atherosclerosis Society. <br><br>Professor Betteridge is co-chair of the executive committee of CARDS, a major primary CVD prevention trial with atorvastatin in type 2 diabetes. He is the UK Principal Investigator and member of the International Steering Committee for PROactive, a major secondary prevention trial with pioglitazone in type 2 diabetes. He is a member of the Joint European Society of Cardiology and European Association for the Study of Diabetes taskforce group on Diabetes and Vascular Disease and was a member of the Medical Research Council Steering Committee for the UKPDS. He is a member of the Project Grants Committee of the British Heart Foundation.<br><br>Professor Betteridge's main clinical interests are in the care of patients with diabetes mellitus and patients with lipid disorders. His main research interests relate to the pathogenesis of atherosclerosis, and in particular the role of lipoprotein metabolism. He has authored over 300 publications in peer-reviewed journals. His books include Lipoproteins in Health and Disease (Edward Arnold, 1999), Diabetes: Current Perspectives (Martin Dunitz, 2000), Lipids and Vascular Disease (Martin Dunitz, 2000), Case Studies in Diabetes (Martin Dunitz, 2003), Lipids and Coronary Heart Disease (Arnold, 2003) and Case Studies in Lipid Management (Informa Healthcare) 2006.</td></tr></table>",
//Ralph DeFronzo = s. Array 19
//Array 54 = Kearney, Mark
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Mark Kearney</strong><br><i>University of Leeds, UK </i><br><br></td></tr><tr><td><img src='images/speakers/kearney.jpg'></td><td>Professor Mark Kearney was born in 1966 and gained his MB ChB from Leeds Medical School in 1989 and DM from the University of Nottingham in 1996. He has been Professor of Cardiology at Leeds University Medical School since 2000 and is currently a senior researcher at the Leeds Institute of Genetics, Health and Therapeutics (LIGHT) Laboratories, University of Leeds .<br><br>Professor Kearney is currently a member of the British Heart Foundation Project Grant Committee I (2006 - 2010) and was a BHF intermediate fellow examining mechanisms linking obesity to endothelial dysfunction. Professor Kearney has received previous funding for on going research projects as well as having had published countless research papers, selected reviews and letters.<br><br>His research fields focus on mechanisms of reduced nitric oxide bioavailability in insulin resistance and related metabolic disorders and prognosis in chronic heart failure. His research interests include clinical endothelial dysfunction, insulin resistance and heart failure. His research into heart failure has included work to improve monitoring of patients and their treatment. His laboratory also explores the mechanistic link between endothelial function and insulin resistance, exploiting gene-modified technologies and state of the art cell biology approaches. </td></tr></table>",
//Array 55 = Seufert, Jochen
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Professor Jochen Seufert, MD, PhD</strong><br><i>University of Freiburg, Freiburg, Germany</i><br><br></td></tr><tr><td><img src='images/speakers/seufert.jpg'></td><td>Professor Jochen Seufert was born in 1964 and gained his medical degree from the University of W&uuml;rzburg, Germany, in 1989. Following a 3-year period at the Massachusetts General Hospital and Harvard University, Boston, USA, where he researched and tutored in endocrinology and metabolism, Professor Seufert returned to W&uuml;rzburg, where he continued specialisation in this field. Since 2001, he has been Assistant Professor and Chief of the Division of Metabolism, Endocrinology and Molecular Medicine at the University of W&uuml;rzburg Medical School. In 2006 he moved to the University of Freiburg Medical School in Germany, where he was promoted to Full Professor of Medicine, Endocrinology and Diabetology and Head of the Division of Endocrinology and Diabetology. <br><br>His main focus is the implementation of novel clinical treatment strategies of diabetes mellitus including novel agents. He also runs an experimental diabetes research laboratory focusing mainly on pancreatic beta-cell research. He has been involved with steering committees of several national and international clinical trials. Professor Seufert’s research has been recognised through a number of awards including the Merck Senior Fellows Award (Endocrine Society, USA), the Schoeller-Junkmann Scientific Award (German Endocrine Society), the Theodor-Frerichs Award (German Association for Internal Medicine) and the Ernst-Friedrich-Pfeiffer-Award (German Diabetes Association). <br><br>Currently he serves on speaker boards of the sections for Diabetes and Metabolism, and Molecular and Cellular Endocrinology of the German Endocrine Society. He also serves as reviewer for several journals in the field including Proceedings of the National Academy of Science, Diabetes, Diabetes Care and Diabetologia.</td></tr></table>",
//Array 56 = Bergenstal, Richard
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Richard M. Bergenstal, MD</strong><br><br></td></tr><tr><td><img src='images/speakers/bergenstal.jpg'></td><td>Richard M. Bergenstal, MD, is an endocrinologist and Executive Director of the International Diabetes Center at Park Nicollet.  He is Clinical Professor in the Department of Medicine at the University of Minnesota and currently serves as President Elect, Science & Medicine of the American Diabetes Association. In 2007, Dr. Bergenstal was named the ADA’s Outstanding Physician Clinician of the Year.<br><br>Dr. Bergenstal received his MD and endocrine training from the University of Chicago where he was an Assistant Professor of Medicine before joining the International Diabetes Center in 1983. His clinical research has focused on glucose control and diabetes complications and he is currently the Principal Investigator of two NIH trials, the Diabetes Control and Complications Trial (DCCT) in type 1 diabetes and the Action to Control Cardiovascular Risks in Diabetes (ACCORD) study in type 2 diabetes. Dr Bergenstal’s clinical expertise includes evaluating the effective use of insulin therapy and how to utilize glucose monitoring (SMBG & CGM) to improve diabetes care. Dr Bergenstal is currently working on how new models of diabetes care can advance health care reform. He teaches nationally and internationally on the importance of patient-centered team care, has been listed in Best Doctors in America since it began in 1992, has published over 100 peer reviewed scientific articles in diabetes and has co-authored the best selling Betty Crocker Diabetes Cookbook.</td></tr></table>",
//Referenten MSD
//Array 57 = Brady, Adrian
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Dr. Adrian J.B. Brady B.Sc (Hons), M.D., F.R.C.P (Glasg), F.R.C.P.E., F.A.H.A.<br>Consultant Cardiologist, Glasgow Royal Infirmary, Glasgow, UK.</strong><br><br></td></tr><tr><td><img src='images/speakers/brady.jpg'></td><td>Dr Brady was born in Edinburgh in 1961, attended Edinburgh Academy, then Edinburgh University Medical School. He graduated in 1985, top of his year twice, with a series of prizes and First Class BSc Honours, Summa Cum Laude. He trained in Cardiology at the Hammersmith Hospital, London Chest Hospital and the National Heart and Lung Institute, London. During his research time Dr Brady won the British Cardiac Society Award and was the first overseas winner of the American Heart Association Young Investigator Award. After two years as Senior Registrar in Birmingham he moved to Glasgow Royal Infirmary as Consultant Cardiologist in 1996. In 1997 he was awarded the Croom Lecture at the Royal College of Physicians of Edinburgh. In addition to general cardiology he is Director of the Hypertension Service and the Echocardiography Service. Until recently he was Associate Medical Director for North Glasgow Hospitals University NHS Trust. <br><br>Dr Brady’s major specialities are the clinical aspects and epidemiology of coronary heart disease, hypertension, heart failure and pulmonary embolism. He was the principal investigator for the Healthwise I and II (40,000 patients); the Performance for Life (80,000 patients); and Ayrshire and Arran Study (19,253 patients) coronary heart disease databases. He also has a long-term interest in pulmonary vascular disease and represents the UK on the European Society of Cardiology Steering Group on pulmonary embolism and is a member of the International Steering Committee for the International Trial of Thrombolysis in Pulmonary Embolism. He is the Principal Investigator for the UK in the international IMPROVE-IT trial (TIMI 40) of statins in acute coronary syndromes (ACS), and the DAL-HEART trial of dalcetrapib in ACS.<br><br>Dr Brady has published 71 papers in medical research journals on the above subjects and also in basic cardiovascular biology. His textbook, “New Perspectives on Hypertension”, is now in its third edition. Dr Brady has given over 60 invited lectures at most of the major cardiovascular congresses including Plenary lectures at the European Society of Cardiology, the American Heart Association, the Japanese Circulation Society and the French Cardiac Society. He has lectured at the Mayo Clinic, in Germany, Sweden, Chile, France, Slovenia, Lithuania, Croatia, Hong Kong, Thailand, Egypt, Saudi Arabia and in Ireland. He has lectured at the British Cardiac Society, British Hypertension Society, British Geriatrics Society and had many other presentations to the British Cardiac Society, British Hypertension Society, European Societies of Cardiology and Hypertension, the International Society of Heart Research and the American Heart Association. He recently completed a lecture tour of China, representing the European Society of Cardiology.<br><br>Dr Brady was elected a Fellow of the American Heart Association in 2003. He was invited to become Visiting Professor of Cardiology at the Mayo Clinic in 2004, and the University of Valparaiso in 2005. Dr Brady was elected to the Executive Committee of the British Hypertension Society 2004-2007, and is currently Secretary of the BHS 2008-2012. He was elected to, and is now Chairman of the Guidelines Committee of the British Cardiovascular Society 2007-2011, and is a member of the ESC Guidelines Development Group. Dr Brady was one of the principal authors of the Scottish national guidelines for coronary heart disease prevention, published 2007. He was an author of the European Society of Cardiology Pulmonary Embolism Guideline, published 2008, and is a member of the 2009 British Thoracic Society guideline committee.<br><br>In his current biggest project Dr Brady leads Football Health Glasgow, a major initiative working with Celtic and Rangers Football Clubs, to improve cardiovascular health for football fans in Glasgow. <br><br>Dr Brady is married with three children. Outside his profession he is devoted his children, his golf, skiing and the piano. Fortunately his children are also mad on golf and skiing, and even play the piano. Dr Brady is yet to win any golf trophies, although Catriona, his elder daughter, has won five. He can only occasionally beat Jamie, his son, at table tennis. Emma, the youngest, cooks better than he does.</td></tr></table>",
//Array 58 = M&uuml;ller-Wieland, Dirk
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Dirk M&uuml;ller-Wieland, MD</strong><br><br></td></tr><tr><td><img src='images/speakers/mueller-wieland.jpg'></td><td>Dirk M&uuml;ller-Wieland, MD, is professor of medicine and chairman of the department of general internal medicine, head of endocrinology, diabetes and metabolism and director of the institute for diabetes research at the Asklepios Clinic St. Georg in Hamburg, Germany.<br><br>1979 to 1985 he went to Medical School in Hamburg and wrote a thesis about the hormonal regulation of cholesterol synthesis. From 1985 to 1987 he was research fellow in the group of Dr. C. R. Kahn, Research Director of the Joslin Diabetes Center, Harvard Medical School, Boston, USA, beginning his scientific work about molecular mechanisms of insulin action and insulin resistance. Dirk M&uuml;ller-Wieland went back to Hamburg 1987 and to Cologne 1991 completing his training in Internal Medicine as well as in Endocrinology, Diabetes and Metabolism. In the year 2001 he took over the chair for clinical biochemistry at the university of Duesseldorf and was chairman of the German Diabetes Center before moving to Hamburg 2006 to take over his current position.<br><br>His current scientific interests are the molecular basis of cardiovascular risk factors and there clinical implications. Here he focuses on specific molecular mechanisms of signal transduction by insulin, growth factors and cytokines and their role in the pathogenesis of insulin resistance (including obesity and/or type 2 diabetes) and their relations to lipid disorders. Recently he and his research group has found for example, that cholesterol-regulated transcription factors (SREBPs) are also phosphorylated by different MAP kinase cascades, mediating effects of insulin, growth factors and cytokines. Therefore these transcription factors appear to be a gene regulatory link between cholesterol metabolism, insulin sensitivity, inflammatory signals and obesity. Now they study the potential clinical implications in different cohorts of patients.<br><br>1995 he received the Bertram-Preis, the highest research award of the German Diabetes Association. Beside publication of numerous papers, including the New England Journal of Medicine and Science, M&uuml;ller-Wieland just edited together with Dr. B. Goldstein the second edition of an international textbook on type 2 diabetes (Informa Health 2008, 520 pages, 60 authors from 11 countries). Currently he serves in the board of the German Diabetes Association as well as of the German Endocrine Society and is editor-in-chief of “Diabetologie und Stoffwechsel”, the scientific journal of the German Diabetes Association with a circulation of more than 7000 per issue, published every second month.</td></tr></table>",
//Array 59 = Lawrence A Leiter
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Lawrence A Leiter</strong><br><br></td></tr><tr><td><img src='images/speakers/leiter.jpg'></td><td>Dr. Lawrence A. Leiter is Head of the Division of Endocrinology and Metabolism, Director of the Lipid Clinic, and Associate Director of the Clinical Nutrition and Risk Factor Modification Centre at St. Michael's Hospital in Toronto. He is also a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.<br><br>Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has held research funding from various agencies including the National Institutes of Health, Medical Research Council of Canada/CIHR and Canadian Diabetes Association and has over 300 publications in peer reviewed journals. He was a co-investigator in many of the landmark diabetes trials including the DCCT, ACCORD, and ADVANCE and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas. He has been involved in many national and international committees and consensus conferences. He has been actively involved in the Canadian Diabetes Association for many years and is a past Chair of its Clinical and Scientific Section. He was Co-Chair of the Canadian Diabetes Association Committee to revise the Clinical Practice Guidelines for the Management of Diabetes in Canada published in 1998 and was on the Steering Committee and Chair of the Macrovascular section for both the 2003 and 2008 revisions. He is also currently involved in Canadian Guideline committees for the management of Lipids, Hypertension, and Obesity. He was Co-chair of the 7th International Congress on Obesity which was held in Toronto in August 1994. For his work, Professor Leiter has received a number of awards including the Canadian Diabetes Association Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service, the 2005 Canadian Society of Endocrinology and Metabolism Educator of the Year Award, and the 2006 Canadian Diabetes Association Gerald S.Wong Award in recognition of significant contribution to the diabetes community.<br><br></td></tr></table>",
//Array 60 = Ronnie Willenheimer
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Ronnie Willenheimer, Lund University, Heart Health Group<br>Dept of Clinical Sciences, Cardiology, Malm&ouml;, Sweden<br>University Hospital MAS, Malm&ouml;, Sweden </strong><br><br></td></tr><tr><td><img src='images/speakers/willenheimer.jpg'></td><td>Medical experience (MD, PhD)<br>MD since 1983. Cardiology specialist since 1994. Associate Professor of Cardiology at Lund University Medical School. Former Head of Echocardiography Unit, Heart Failure Unit and Outpatient Unit, former Research Dirctor and former Deputy Director of the Department of Cardiology, University Hospital Malm&ouml;, Lund University Medical School. Currently Medical Director of Heart Health Group in Malm&ouml;, Sweden.<br><br>Research <br>PhD degree in 1998. Research in congestive heart failure, ischemic heart disease, diabetes and the heart, echocardiography in heart disease and hypertension, early cardiovascular disease and prevention of cardiovascular disease. Investigator in more than 100 clinical studies. Swedish co-ordinator for numerous multicentre clinical trials on cardiovascular diseases, including several worldwide mega-trials. Principal investigator and steering committee member of international multicentre clinical studies on heart failure and other cardiovascular diseases such as the OPTIMAAL, HEAVEN, CIBIS III, SEAS, RED-HF and SHIFT trials. Currently tutor for 6 PhD students and previously for 7 students with PhD degree.<br><br>Publications <br>More than 150 original papers in peer-reviewed journals, books, book chapters and review articles. Numerous abstracts at World, European and American congresses of Cardiology and symposia. <br><br>Commissions of trust<br>Past Vice President of the Swedish Society of Cardiology and past President of the Working Group on Heart Failure of the Swedish Society of Cardiology. Reviewer for several leading multidisciplinary and cardiovascular journals. Editorial board member of international journals, such as European Journal of Heart Failure.</td></tr></table>",
//Array 61 = Peter Kurtzhals
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>Peter Kurtzhals<br>Novo Nordisk, Denmark</strong><br><br></td></tr><tr><td><img src='images/speakers/kurtzhals.jpg'></td><td>Peter Kurtzhals is Senior Vice President, Head of Diabetes Research and member of the Management Board at Novo Nordisk A/S.<br><br>He has held positions as Principal Scientist in the Insulin Research group at Novo Nordisk, as a Visiting Scientist at the Joslin Diabetes Center, and Harvard Medical School in Boston, and as Head of Diabetes Biology at Novo Nordisk. He was appointed Vice President and Head of Discovery Biology in 2000 and Senior Vice President in 2001 and has been the Scientific Coordinator for Novo Nordisk's insulin analogue projects, including insulin aspart and insulin detemir. Prior to joining Novo Nordisk in 1990, he worked as an Assistant Professor at The Danish University of Pharmaceutical Sciences, from where he holds MSc and PhD degrees.<br><br>Peter Kurtzhals chairs the Research Policy Committee of the The Danish Association of the Pharmaceutical Industry. He is a member of the Research Directors' Group of the European Federation of Pharmaceutical Industries and Associations, the Scientific Advisory Board of The Faculty of Pharmaceutical Sciences, University of Copenhagen, the Board of Medicon Valley Alliance and the Board of the Steno Diabetes Centre.</td></tr></table>",
//Array 62 = F. Snoek
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>F. Snoek<br>(NL)</strong><br><br></td></tr><tr><td><img src='images/speakers/snoek.jpg'></td><td></td></tr></table>",
//Array 63 = A. Jacobson
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>A. Jacobson (US)</strong><br><br></td></tr><tr><td><img src='images/speakers/jacobson.jpg'></td><td></td></tr></table>",
//Array 64 = A. Krentz
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>A. Krentz (UK)</strong><br><br></td></tr><tr><td><img src='images/speakers/krentz.jpg'></td><td></td></tr></table>",
//Array 65 = J. Skyler
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>J. Skyler (US)</strong><br><br></td></tr><tr><td><img src='images/speakers/skyler2.jpg'></td><td></td></tr></table>",
//Array 66 = M. Diamant
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>M. Diamant (NL)</strong><br><br></td></tr><tr><td><img src='images/speakers/diamant.jpg'></td><td></td></tr></table>",
//Array 67 = G. Fulcher
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>G. Fulcher (AU)</strong><br><br></td></tr><tr><td><img src='images/speakers/fulcher.jpg'></td><td></td></tr></table>",
//Array 68 = I. Raz
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>I. Raz (IL)</strong><br><br></td></tr><tr><td><img src='images/speakers/raz.jpg'></td><td></td></tr></table>",
//Array 69 = S. Edelmann
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>S. Edelmann (US)</strong><br><br></td></tr><tr><td><img src='images/speakers/edelmann.jpg'></td><td></td></tr></table>",
//Array 70 = J. Johnson (CA)
"<span style='background-color:FFFFFF;color:#666666;text-align:left;'><table border='0' cellspacing='0' cellpadding='5'><tr><td colspan='2'><strong>J. Johnson (CA)</strong><br><br></td></tr><tr><td><img src='images/speakers/johnson.jpg'></td><td></td></tr></table>"
// :::::::::: Texte f&uuml;r die Info-Box bis hier
);


overdiv="0";


function popLayer(a)
{
if(!descarray[a]){descarray[a]="<font color=red>Dieses PopUp (#"+a+") ist nicht korrekt definiert - Beschreibung fehlt</font>";
}

desc = "<table style='border:1px solid #5F5F5F' cellspacing=0 cellpadding=10 border=0><tr><td style='font-size:11px;color:#000000;background-color:#F8F8F8'>\n"
        +descarray[a]
        +"\n</td></tr></table>";
if(navigator.family =="nn4") {
        document.object1.document.write(desc);
        document.object1.document.close();
        document.object1.left=x+15;
        document.object1.top=y-5;
        }
else if(navigator.family =="ie4"){
        object1.innerHTML=desc;
        object1.style.pixelLeft=x+15;
        object1.style.pixelTop=y-5;
        }
else if(navigator.family =="gecko"){
        document.getElementById("object1").innerHTML=desc;
        document.getElementById("object1").style.left=x+15;
        document.getElementById("object1").style.top=y-5;
        }
}


//  versteckt die PopUp-Box
function hideLayer(){
if (overdiv == "0") {
        if(navigator.family =="nn4") {eval(document.object1.top="-500");}
        else if(navigator.family =="ie4"){object1.innerHTML="";}
        else if(navigator.family =="gecko") {document.getElementById("object1").style.top="-500";}
        }
}


//  &uuml;berwacht Maus-Position / plaziert die Box dementsprechend
var isNav = (navigator.appName.indexOf("Netscape") !=-1);

function handlerMM(e){

// entweder feste x/y-Position f&uuml;r die Info-Box
// x = 300; // Infobox x-Position bei 300 von links
// y = 0;   // Infobox y-Position bei 0 (oben)
// oder Plazierung neben Mauszeiger


x = (isNav) ? e.pageX : event.clientX + document.body.scrollLeft;
y = (isNav) ? e.pageY : event.clientY + document.body.scrollTop;

}

if (isNav){document.captureEvents(Event.MOUSEMOVE);}
document.onmousemove = handlerMM;
//  End -->
